A Standardized and Quality-Controllable Protocol of Constructing Individual Tissue-Engineered Grafts Applicable to Treating Large Bone Defects

Xing, Junchao; Lu, Yanzhu; Cui, Yigong; Zhu, Xiaobo; Luo, Fei; Xie, Zhiyong; Wu, Xiang; Deng, Min‐Zhi; Xu, Jianzhong; Hou, Tianyong

doi:10.1089/ten.tec.2018.0323

Cited by 9 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone bioactive materials（BBMs）are supposed to be able to promote osteogenesis by inducing MSCs to differentiate into osteoblasts [ 20 , 21 ]. Thus, both in vitro osteogenic differentiation of MSCs [ [22] , [23] , [24] , [25] ] and in vivo osteogenesis are necessary to evaluate the performance of BBMs [ [26] , [27] , [28] , [29] , [30] , [31] ]. The research paradigm in detecting the fate of MSCs regulated by BBMs is evolving from low-throughput experimental design to high-throughput experimental design.…”

Section: Introductionmentioning

confidence: 99%

Development of methods for detecting the fate of mesenchymal stem cells regulated by bone bioactive materials

Jiang

Liu

Wang

et al. 2021

Bioactive Materials

View full text Add to dashboard Cite

The fate of mesenchymal stem cells (MSCs) is regulated by biological, physical and chemical signals. Developments in biotechnology and materials science promoted the occurrence of bioactive materials which can provide physical and chemical signals for MSCs to regulate their fate. In order to design and synthesize materials that can precisely regulate the fate of MSCs, the relationship between the properties of materials and the fate of mesenchymal stem cells need to be clarified, in which the detection of the fate of mesenchymal stem cells plays an important role. In the past 30 years, a series of detection technologies have been developed to detect the fate of MSCs regulated by bioactive materials, among which high-throughput technology has shown great advantages due to its ability to detect large amounts of data at one time. In this review, the latest research progresses of detecting the fate of MSCs regulated by bone bioactive materials (BBMs) are systematically reviewed from traditional technology to high-throughput technology which is emphasized especially. Moreover, current problems and the future development direction of detection technologies of the MSCs fate regulated by BBMs are prospected. The aim of this review is to provide a detection technical framework for researchers to establish the relationship between the properties of BMMs and the fate of MSCs, so as to help researchers to design and synthesize BBMs better which can precisely regulate the fate of MSCs.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of methods for detecting the fate of mesenchymal stem cells regulated by bone bioactive materials

Jiang

Liu

Wang

et al. 2021

Bioactive Materials

View full text Add to dashboard Cite

show abstract

“…Finally, there were some limitations and difficulties when working with MSCs, such as long construction period, strict quality control and safety criteria, and particular equipment and qualified technicians. This issue may be addressed in accordance with the standardized protocol previously described by our group 7 . Larger-sample, multicenter, and prospective comparative trials are called on for further identification.…”

Section: Discussionmentioning

confidence: 99%

“…After the procedures, the antigenic components of allogeneic bone were completely removed. Complying with the standardized protocol previously described by our group 7 , patient-specific iTEBs were constructed using autologous MSCs and allogeneic decalcificated bone matrix (DBM). Briefly, DBM were sectioned into blocks (5 × 5 × 5 mm) and soaked into patient-specific autologous serum for more than 2 d. For cell harvest, 50 ml of StemPro ® MSC SFM XenoFree Supplement and 5 ml of 200 mM l -glutamine were aseptically added into 445 ml of StemPro ® MSC SFM Basal Medium (all from GiBCO, NY, USA) to prepare 500 ml of basic culture medium (BCM).…”

Section: Methodsmentioning

confidence: 99%

Comparison of Individual Tissue-Engineered Bones and Allogeneic Bone in Treating Bone Defects: A Long-Term Follow-Up Study

Peng

Zhou

et al. 2020

Cell Transplant

Self Cite

View full text Add to dashboard Cite

The treatment of bone defects has always been a challenge for orthopedic surgeons. The development of tissue engineering technology provides a novel method for repairing bone defects and has been used in animal experiments and clinical trials. However, there are few clinical studies on comparing the long-term outcomes of tissue-engineered bones (TEBs) and other bone grafts in treating bone defects, and the long-term efficiency of TEBs remains controversial. Therefore, a study designed by us was aimed to compare the long-term efficacy and safety of individual tissue-engineered bones (iTEBs) and allogeneic bone granules (ABGs) in treating bone defects caused by curettage of benign bone tumors and tumor-like lesions. From September 2003 to November 2009, 48 patients who received tumor curettage and bone grafting were analyzed with a mean follow-up of 122 mo (range 60 to 173 mo). Based on implant style, patients were divided into groups of iTEBs ( n = 23) and ABGs ( n = 25). Postoperatively, the healing time, healing quality, incidence of complications, and functional scores were compared between the two groups. The Musculoskeletal Tumor Society functional evaluation system and Activities of Daily Living Scale scores were significantly improved in both groups with no significant difference. The average healing time of ABGs was longer than that of iTEBs ( P < 0.05). At the final follow-up, iTEBs had a better performance in the bone healing quality evaluated by modified Neer classification ( P < 0.05). In the group of iTEBs, the complication and reoperation rate was lower than that in the group of ABGs, with no tumorigenesis or immune rejection observed. In summary, for treating bone defects caused by tumor curettage, iTEBs were safe, effective, and tagged with more rapid healing speed, better healing outcome, and lower complication and reoperation rate, in comparison with ABGs.

show abstract

“…This growth is due to the creation of new processing protocols that improve the quality of biomaterials [ 3 ]. For example, Kobayashi et al proposed a standard protocol to prepare platelet-rich fibrin membranes [ 4 ], Zuidema et al standardized the protocol for the correct rheological characterization of hydrogels for tissue engineering [ 5 ], and Xing et al evaluated a quantity-controllable protocol for constructing individual tissue-engineered grafts [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Incorporation of Elastin to Improve Polycaprolactone-Based Scaffolds for Skeletal Muscle via Electrospinning

et al. 2021

View full text Add to dashboard Cite

Skeletal muscle regeneration is increasingly necessary, which is reflected in the increasing number of studies that are focused on improving the scaffolds used for such regeneration, as well as the incubation protocol. The main objective of this work was to improve the characteristics of polycaprolactone (PCL) scaffolds by incorporating elastin to achieve better cell proliferation and biocompatibility. In addition, two cell incubation protocols (with and without dynamic mechanical stimulation) were evaluated to improve the activity and functionality yields of the regenerated cells. The results indicate that the incorporation of elastin generates aligned and more hydrophilic scaffolds with smaller fiber size. In addition, the mechanical properties of the resulting scaffolds make them adequate for use in both bioreactors and patients. All these characteristics increase the biocompatibility of these systems, generating a better interconnection with the tissue. However, due to the low maturation achieved in biological tests, no differences could be found between the incubation with and without dynamic mechanical stimulation.

show abstract

A Standardized and Quality-Controllable Protocol of Constructing Individual Tissue-Engineered Grafts Applicable to Treating Large Bone Defects

Cited by 9 publications

References 22 publications

Development of methods for detecting the fate of mesenchymal stem cells regulated by bone bioactive materials

Development of methods for detecting the fate of mesenchymal stem cells regulated by bone bioactive materials

Comparison of Individual Tissue-Engineered Bones and Allogeneic Bone in Treating Bone Defects: A Long-Term Follow-Up Study

Incorporation of Elastin to Improve Polycaprolactone-Based Scaffolds for Skeletal Muscle via Electrospinning

Contact Info

Product

Resources

About